Systemic Sclerosis-Associated PAH Completed Phase 2 Trials for Methylprednisolone (DB00959)

IndicationStatusPhase
DBCOND0092117 (Systemic Sclerosis-Associated PAH)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01086540Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)Treatment